Venetoclax Combined with Obinutuzumab for Untreated CLL (Chronic Lymphocytic Leukemia)

One-year fixed-duration venetoclax combined with obinutuzumab is now an established standard treatment for patients with treatment - naive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Five-year follow-up data from the CLL14 trial that demonstrated the high efficacy of this combination in CLL provides an excellent opportunity to study the outcomes of patients long after treatment completion.
Dr. Brian Koffman reviews the study results presented at the European Hematology Association (EHA) Annual Congress in 2023.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society